

D. DIVE, C. Ernon and A. Brouwers  
University Hospital of Liège, Belgium

## Cladribine: 14 years brain atrophy and clinical follow-up

10 patients (5M-5F)

Mean age at diagnosis : 38.1 y

CLARITY 2 years → CLARITY EXTENSION: all patients

Mean treatment gap period : 322 days

1 patient treated with Rebif44 during the gap period due to relapse and MRI activity

Last treatment tablet : from March 2008 to April 2010


3 patients treated with an another therapy since CLARITY EXTENSION due to relapses

0/10 patients entered in SP-MS phase




One pregnancy after the study period – normal baby without specific disease activity for the mother

No specific adverse event


1 patient: persistent grade I lymphopenia after 11 years





### Long-term MRI metrics post Clarity Extension



### Long term brain atrophy since Clarity



### Normalized relative lateral ventricles volume



### Long term post-Clarity extension MRI metrics

Whole brain, lateral ventricles and grey matter volumes within the normal range after correction for age

### Lateral ventricles follow-up since Clarity entry

ITK snap semi-automated segmentation

Normalised and relative volumes FU

LV volume extremely stable in the NEDA 3 patients group

LV volume dynamic is different for patients who needed another therapy

Long term effects of induction therapy with Cladribine need to be explored in larger cohorts

Lateral ventricles volumes FU could be useful at an individual level